Loading company…
Viva In Vitro develops diagnostic tools for assessing the severity of sepsis.
Founded in 2021 and based in Murcia, Spain, Viva In Vitro’s VIVA-ELISA® test is designed to predict sepsis severity. The company reported clinical trials involving 158 patients and further evaluations with more than 360 patients in Spanish hospitals. In July 2024, it raised EUR 1.3 mn led by Murcia Emprende.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in